2026-09-14T13:02:47Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/276972026-09-11T15:33:08Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc González-Bertolín, Isabel author Alcolea, Sonia author Alonso, Patricia author Arroyas, María author Fernández Castiella, Isabel author Echavarren, Iciar author Iglesias-Caballero, Maria author Casas Flecha, Inmaculada author García-García, María Luz author Calvo, Cristina author 2025-10-01 Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab's safety as a preventive strategy. González-Bertolín, I., Alcolea, S., Alonso, P., Arroyas, M., Fernández Castiella, I., Echavarren, I., Iglesias-Caballero, M., Casas, I., García-García, M. L., & Calvo, C. (2025). Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season. Pediatric Infectious Disease Journal, 44(10), 1009–1011. https://doi.org/10.1097/INF.0000000000004920. 10.1097/INF.0000000000004920 The Pediatric Infectious Disease Journal https://hdl.handle.net/20.500.12105/27697 Antibody-dependent enhancement Immunization Nirsevimab Respiratory syncytial virus Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.